Key points are not available for this paper at this time.
Metabolic syndrome (MetS) is a complex condition defined by central obesity, insulin resistance, dyslipidemia, and systemic inflammation. Kefir, a fermented beverage rich in probiotics and beneficial compounds, has emerged as a functional food that may offer metabolic advantages. Nevertheless, preclinical results have been variable. This systematic review and meta-analysis aimed to assess the influence of kefir and its derived compositions on parameters associated with MetS, inflammation, and oxidative stress in rodent studies. A comprehensive literature search was conducted in PubMed, Scopus, AMED, and LILACS through June 2024. Eligible studies involving kefir interventions in rodent MetS models were included. Data extraction followed PRISMA guidelines, with the risk of bias assessed using the CAMARADES and SYRCLE tools. Meta-analyses were performed with a random effects model. Thirty-eight studies involving 1462 rodents (mice and rats) were analyzed. Kefir significantly reduced body weight gain in both mice (MD = -3.33; 95% CI: -4.89 to -1.77) and rats (MD = -41.53; 95% CI: -54.33 to -28.72). In mice, triglycerides and LDL-C levels decreased significantly; in rats, kefir lowered total cholesterol and triglycerides. Insulin levels were reduced (MD = -0.69; 95% CI: -1.16 to -0.22), suggesting improved insulin sensitivity. Several studies also reported reductions in TNF-α, IL-1β, and IL-6. Despite promising results, the high heterogeneity and methodological variability emphasize the need for standardized preclinical protocols and clinical validation. These findings support the role of kefir as a functional food for metabolic health promotion.
Qaisrani et al. (Thu,) studied this question.